Semnur Pharmaceuticals, Inc.

Semnur Pharmaceuticals, Inc. (ticker: DECA) is a clinical-stage pharmaceutical company that became publicly listed through a de-SPAC merger with Denali Capital Acquisition Corp, a healthcare-focused blank check company that completed its initial public offering in 2021. Operating in the life sciences and chronic pain therapeutics sector, Semnur filed a quarterly report on Form 10-Q with the SEC on August 15, 2023, reflecting its ongoing status as a post-merger public entity developing non-opioid treatments for pain conditions. For complete SPAC deal data, sponsor details, and filing history on DECA and hundreds of other transactions, sign up for full access at SpacDesk.